DelveInsight’s “Friedreich’s Ataxia Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Friedreich’s Ataxia pipeline landscape. It covers the Friedreich’s Ataxia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Friedreich’s Ataxia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Friedreich’s Ataxia Pipeline? Click here to explore the therapies and trials making headlines @ Friedreich’s Ataxia Pipeline Outlook Report

Key Takeaways from the Friedreich’s Ataxia Pipeline Report

• On 07 October 2025, Biogen conducted a study is to learn more about the safety of RTA 408 and how it affects physical effort, movement, coordination, and how participants feel in daily life. In this study, researchers are learning more about RTA 408, also known as omaveloxolone, BIIB141, or SKYCLARYS®.
• DelveInsight’s Friedreich’s Ataxia Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Friedreich’s Ataxia treatment.
• The leading Friedreich’s Ataxia Companies such as PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics and others.
• Promising Friedreich’s Ataxia Therapies such as EPI-743, RT001, Idebenone, Lu AA24493, MIB-626, DT-216P2, CTI-1601, MIN-102 and others.

Want to know which companies are leading innovation in Friedreich’s Ataxia? Dive into the full pipeline insights @ Friedreich’s Ataxia Clinical Trials Assessment

The Friedreich’s Ataxia Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Friedreich’s Ataxia Pipeline Report also highlights the unmet needs with respect to the Friedreich’s Ataxia.

Friedreich’s Ataxia Overview

Friedreich’s Ataxia (FRDA) is a genetic, progressive, neurodegenerative movement disorder, with a typical age of onset between 10 and 15 years. Initial symptoms may include unsteady posture, frequent falling, and progressive difficulty in walking due to impaired ability to coordinate voluntary movements (ataxia). Affected individuals often develop slurred speech (dysarthria), characteristic foot deformities, and an irregular curvature of the spine (scoliosis).

Friedreich’s Ataxia Emerging Drugs Profile

• RT 001: Retrotope

RT001 is a clinical-stage isotopically stabilized, synthetic linoleic acid (LA) discovered and developed with Retrotope’s novel platform technology. This platform is designed to combat the oxidative stress and cellular degeneration that arises from lipid peroxidation (LPO). It is currently in phase III stage of development for Friedreich’s ataxia and is being developed by Retrotope.

• Leriglitazone: Minoryx Therapeutics

Leriglitazone (MIN-102) is a novel, orally bioavailable and selective PPAR gamma agonist with a potential best-in-class profile indicated for CNS diseases. It is one of the several metabolites of pioglitazone and has a demonstrated sufficient brain penetration and favorable safety profile in humans, allowing PPAR gamma engagement in the CNS above the level that can be safely achieved with pioglitazone and other glitazones. It showed robust preclinical proof-of-concept in animal models of multiple diseases by modulating pathways leading to mitochondrial dysfunction, oxidative stress, neuroinflammation, demyelination and axonal degeneration. It is currently in phase II stage of development and is being developed by Minoryx Therapeutics.

If you’re tracking ongoing Friedreich’s Ataxia Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Friedreich’s Ataxia Treatment Drugs

The Friedreich’s Ataxia Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Friedreich’s Ataxia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Friedreich’s Ataxia Treatment.
• Friedreich’s Ataxia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Friedreich’s Ataxia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Friedreich’s Ataxia market.

Friedreich’s Ataxia Companies

PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics and others.

Friedreich’s Ataxia Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Friedreich’s Ataxia Products have been categorized under various Molecule types such as,

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

From emerging drug candidates to competitive intelligence, the Friedreich’s Ataxia Pipeline Report covers it all – check it out now @ Friedreich’s Ataxia Market Drivers and Barriers, and Future Perspectives

Scope of the Friedreich’s Ataxia Pipeline Report

• Coverage- Global
• Friedreich’s Ataxia Companies- PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics and others.
• Friedreich’s Ataxia Therapies- EPI-743, RT001, Idebenone, Lu AA24493, MIB-626, DT-216P2, CTI-1601, MIN-102 and others.
• Friedreich’s Ataxia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Friedreich’s Ataxia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Friedreich’s Ataxia Treatment landscape in this detailed analysis @ Friedreich’s Ataxia Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Friedreich’s Ataxia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Friedreich’s Ataxia– DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Friedreich’s Ataxia Collaboration Deals
9. Late Stage Products (Phase III)
10. RT 001: Retrotope
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Leriglitazone: Minoryx Therapeutics
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. CTI-1601: Larimar Therapeutics
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. LX-2006: LEXEO Therapeutics
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Friedreich’s Ataxia Key Companies
23. Friedreich’s Ataxia Key Products
24. Friedreich’s Ataxia- Unmet Needs
25. Friedreich’s Ataxia- Market Drivers and Barriers
26. Friedreich’s Ataxia- Future Perspectives and Conclusion
27. Friedreich’s Ataxia Analyst Views
28. Friedreich’s Ataxia Key Companies
29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/friedreich-ataxia-pipeline-insight